Recently, the stock of Taysha Gene Therapies ($NASDAQ:TSHA) has seen a significant stock investment from NFL Quarterback Eli Manning. This marks a major milestone for the company as it continues to grow and expand its reach. Taysha Gene Therapies is a biotechnology company that focuses on developing gene therapies to treat rare neurological disorders. They have a number of crucial partnerships with leading research institutions, including the University of Texas Southwestern Medical Center and the Texas Institute for Brain Injury and Repair, helping them to create innovative treatments for neurological conditions. His investment is seen as a show of confidence in Taysha Gene Therapies and their potential for groundbreaking therapies. This news has sent shockwaves through the biotechnology industry, as more people take notice of this innovative company.
It is clear that Manning believes in their mission and has made a substantial financial commitment to their future. Taysha Gene Therapies is an emerging leader in the biotechnology field. With Manning’s financial backing, the company has solidified its place in the industry as it continues to develop treatments for rare neurological diseases. It will be exciting to see what the future holds for Taysha Gene Therapies and its investors.
The stock opened at $1.7 before closing at $1.8, representing a 5.9% increase from the previous closing price of $1.7. This marks a major increase in stock value for the company, which is now seeing improved investor confidence. With the new influx of capital from Eli Manning, TGT now has new funding to continue its operations and pursue further research and development in the field of genetic therapies. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for TSHA. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for TSHA. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for TSHA. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for TSHA are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has just completed an analysis of the financials of TAYSHA GENE THERAPIES, and we have identified that it is classified as ‘cheetah’. This type of company typically has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Given the nature of the company, we believe that investors who prioritize growth over stability would be interested in TAYSHA GENE THERAPIES. The company has an intermediate health score of 4/10 considering its cashflows and debt, which suggests that it might be able to pay off debt and fund future operations. In terms of its financial metrics, TAYSHA GENE THERAPIES is strong in growth, and weak in asset, dividend, and profitability. Investors should be aware of this before investing in the company, and should weigh the pros and cons carefully. More…
Star Chart Analysis
The Company focuses on developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations. Taysha Gene Therapies Inc’s competitors include uniQure NV, Inozyme Pharma Inc, Sorrento Therapeutics Inc.
UniQure NV is a Dutch holding company that operates in the biopharmaceutical industry. The company researches, develops, and commercializes gene therapies. As of 2022, UniQure NV has a market cap of 884.11M and a Return on Equity of -12.84%. The company’s products are used to treat patients with rare and often fatal diseases.
Inozyme Pharma Inc is a biopharmaceutical company that focuses on developing treatments for disorders of calcification. The company’s lead product candidate, ENB-0040, is in clinical development for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to defective bone formation and kidney dysfunction. Inozyme also has two other product candidates in development for the treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumoral calcinosis (TC).
Inozyme Pharma Inc has a market cap of 88.72M as of 2022. The company’s Return on Equity is -48.16%. Inozyme Pharma Inc focuses on developing treatments for disorders of calcification. The company’s lead product candidate, ENB-0040, is in clinical development for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to defective bone formation and kidney dysfunction. Inozyme also has two other product candidates in development for the treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumoral calcinosis (TC).
– Sorrento Therapeutics Inc ($NASDAQ:SRNE)
Sorrento Therapeutics Inc. is a biopharmaceutical company that engages in the research, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases. The company’s market cap is 715.42M as of 2022 and has a return on equity of -190.34%. Sorrento Therapeutics is headquartered in San Diego, California.
This appears to have had a positive effect on the stock price, as the price moved up significantly on the same day. Investors may want to consider investing in the company, as its stock price has been quite volatile in the past few months and could potentially yield high returns. However, it is important to keep in mind that investing in any stock carries with it risks, so doing proper research and having a sound investment strategy is essential.